Daily Stock Analysis, BGNE, BeiGene Ltd, priceseries

BeiGene Ltd. Daily Stock Analysis
Stock Information
Open
181.74
Close
182.38
High
185.36
Low
179.59
Previous Close
182.55
Daily Price Gain
-0.17
YTD High
210.35
YTD High Date
Nov 25, 2019
YTD Low
108.00
YTD Low Date
Jan 3, 2019
YTD Price Change
46.35
YTD Gain
34.07%
52 Week High
210.35
52 Week High Date
Nov 25, 2019
52 Week Low
108.00
52 Week Low Date
Jan 3, 2019
52 Week Price Change
45.56
52 Week Gain
33.30%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 23. 2017
32.39
Feb 7. 2017
34.41
11 Trading Days
6.22%
Link
LONG
Feb 10. 2017
36.00
Feb 23. 2017
37.84
8 Trading Days
5.11%
Link
LONG
Apr 24. 2017
37.61
May 4. 2017
39.82
8 Trading Days
5.88%
Link
LONG
Jun 16. 2017
41.56
Jul 24. 2017
72.26
25 Trading Days
73.86%
Link
LONG
Sep 13. 2017
75.61
Oct 12. 2017
103.49
21 Trading Days
36.87%
Link
LONG
Jan 17. 2018
102.63
Feb 6. 2018
125.11
14 Trading Days
21.91%
Link
LONG
Feb 14. 2018
129.24
Feb 28. 2018
145.52
9 Trading Days
12.60%
Link
LONG
May 29. 2018
192.45
Jun 11. 2018
204.40
9 Trading Days
6.21%
Link
LONG
Nov 20. 2018
125.82
Dec 6. 2018
139.25
10 Trading Days
10.67%
Link
LONG
Mar 29. 2019
132.00
Apr 11. 2019
138.70
9 Trading Days
5.08%
Link
LONG
Aug 12. 2019
135.35
Aug 26. 2019
142.36
10 Trading Days
5.18%
Link
LONG
Oct 14. 2019
122.50
Dec 2. 2019
202.31
34 Trading Days
65.15%
Link
Company Information
Stock Symbol
BGNE
Exchange
NasdaqGS
Company URL
http://www.beigene.com
Company Phone
13459494123
CEO
John V. Oyler
Headquarters
-
Business Address
C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, CAYMAN ISLANDS KY1-1108
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001651308
About

BeiGene Ltd. operates as a holding company, which engages in the research and development of biopharmaceutical products. It develops immuno-oncology drugs for cancer treatment. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Description

Chinese biotech developing cancer therapies for China and global markets.